Curatis Holding Ag · SIX:CURN
Curatis — Investor Presentation (June 2026)
19 slides from Curatis's investor presentation, June 2026
Slide 1: Fast Growing Commercial Base & Blockbuster Project Ready for Phase III
Fast Growing Commercial Base & Blockbuster Project Ready for Phase III Investor Presentation June 2026
Slide 2: In a nutshell
In a nutshell ▪ The company was founded in 2002 and is listed on SIX since April 2024 (SIX:CURN) ▪ Curatis has continuously expanded its sales portfolio, and currently distributes over 40 products in Switzerland ▪ With Haemopressin (terlipressin) Curatis has developed a pharmaceutical product, launc
Slide 3: Vision: We are a leading provider of specialist medicines in Europe and beyond
Vision: We are a leading provider of specialist medicines in Europe and beyond We search for innovative medicines for the prevention, diagnosis and treatment of rare diseases and other niche areas. We commercialize and bring products to market.
Slide 4: Distribution of specialist medicines
Distribution of specialist medicines Growing and profitable distribution business Switzerland ▪ Curatis sales business currently focused on Switzerland ▪ >40 products distributed in Switzerland ▪ Revenues in 2025: >10m CHF ▪ Revenue growth 2025 vs 2024 = 13%; projected revenue growth 2026 vs 2025 =
Slide 5: Priority Project: Development pipeline
Development pipeline Indication Project Clinical development I IIa IIb Pivotal Phase III MA Priority Project Peritumoral brain edema Registration enabling secondary to malignant brain C-PTBE-01 study tumors (corticorelin) Migraine with aura C-AM-01 Medication overuse headache C-MOH-01 Search for inf
Slide 6: Corticorelin for the treatment of Peritumoral Brain Edema (PTBE)
Corticorelin for the treatment of Peritumoral Brain Edema (PTBE)
Slide 7: Corticorelin: Phase III ready - a breakthrough in PTBE
Corticorelin: Phase III ready - a breakthrough in PTBE Curatis’s lead project, corticorelin, redefines the treatment of peritumoral brain edema (PTBE), addressing a very high unmet medical need Key opportunity highlights Characteristics and benefits of C-PTBE-01 (corticorelin) Active substance Peak
Slide 8: Peritumoral Brain Edema: Very high unmet medical need
Peritumoral Brain Edema: Very high unmet medical need Definition Impact Accumulation of extracellular fluid around brain Causes headaches, seizures, cognitive tumors causing brain compression and functional impairment, and life-threatening intracranial impairment pressure Limitations of current trea
Slide 9: Corticorelin: clinical benefits
Corticorelin: clinical benefits ▪ Corticorelin has demonstrated an exceptional safety profile and efficacy in reducing PTBE while minimizing steroid- related toxicity in up to phase III trials1): • There were no adverse events apart from higher local Injection-site reaction in the corticorelin group
Slide 10: Positioning of corticorelin in PTBE
Positioning of corticorelin in PTBE Positioning Current Future Standard of care Standard of care Efficacy PTBE Corticosteroids (e.g., Corticosteroids plus Corticorelin Dexamethasone) Strong Corticosteriod tapering/elimination Safety/QoL A chronic add-on to acute corticosteroid treatment for adult pa
Slide 11: The market / Market exclusivity
The market / Market exclusivity Significant Market Opportunity Strong IP & Market Exclusivity ▪ Approx. 190,000 patients are affected by peritumoral ▪ Biologics license application: 12 years of market brain edema in the USA exclusivity in the USA ▪ Globally over 500,000 patients may suffer from ▪ Da
Slide 12: Life cycle opportunities
Life cycle opportunities Presentations Expansion Indications ▪ Primary brain tumors in children and adults ▪ Pre-filled syringe / Auto-injector / Pen ▪ Potentiation of anti-VGEF tumor therapies ▪ Slow release ▪ Cerebral edema 12
Slide 13: Strategic partnership with Neupharma for Japan
Strategic partnership with Neupharma for Japan ▪ Access to one of the world’s largest pharma markets ▪ Experienced orphan-drug partner with proven development and commercialization track record ▪ Total deal value up to CHF 83.5 million plus royalties of up to 20% on sales ▪ ~60,000 in Japan and ~500
Slide 14: Team
Team
Slide 15: Board of Directors and Management
Board of Directors and Management Board of Directors Dr. Marian Borovsky Günter Graubach ▪ Non-executive Chairman of the Boar d of Dir ec tors ▪ Founder and executive member of t he Board of Directors ▪ Former General Counsel of Actelion ▪ Formerly: Roche, Santhera Dr. Silvio Inderbitzin Dr. Roland
Slide 16: Advisory Board
Advisory Board Advisory Board Stewart Goldman, MD Prof. Dr. med. Andreas Gantenbein • Internationally renowned pediatric oncologist, Chair of ▪ Expert in neurology, including the Department of Child Health at the University of electroencephalography, electrone uro-myography, Arizona College of Medic
Slide 17: Takeaways
Takeaways Cash flow ▪ Profitable distribution business from operating activities ▪ Strong sales growth ▪ High unmet need for medicine to treat PTBE effectively without severe, systemic side effects of corticosteroids / Lead project potentially no limitation to underlying chemo- or modern immunothera
Slide 18: Important Notice and Disclaimer
Important Notice and Disclaimer THIS DOCUMENT DO ES NO T CONSTITUTE A PRO SPECTUS W ITHIN THE MEANING O F SW ISS FINANCIAL SERVICES ACT (“FINSA”), NOR A PROSPECTUS UNDER ANY O THER APPLICABLE LAWS AND SHOULD NOT BE TREATED AS OFFERING MATERIALS OF AN Y SORT AND IS FO R INFORMATION PURPO SES ONLY. TH
Slide 19: Slide 19